Optiscan unveils high-tech imaging device for veterinarians
The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry.
The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses.
With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster.
'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.'
Optiscan chief executive officer and managing director Camile Farah
Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options.
The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week.
Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.'
Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
3 days ago
- Sydney Morning Herald
Melbourne breast cancer trial to test Optiscan imaging device
ASX-listed medical technology company Optiscan Imaging has started recruiting up to 50 patients for a Royal Melbourne Hospital clinical trial of its innovative precision surgery and digital pathology imaging devices, aiming to improve a common breast cancer surgery. The groundbreaking clinical study will utilise Optiscan's InVue microscopic precision surgery device, as well as its InForm digital pathology imaging system, to create a new, improved treatment regimen for breast cancer patients. The company will investigate the clinical workflow and real-time imaging capabilities of the two platforms in its first in-human breast cancer study. Optiscan will use data from the trial in its submissions for United States Food and Drug Administration (FDA) registration for the devices. Surgeons will use the InVue device during surgery to capture live imaging data from a woman's breast tissue after removing a tumour. It will provide the surgical team with immediate feedback on tumour clearance, ensuring there is a margin of healthy breast tissue around the site where the tumour was removed. Achieving a clear surgical margin, where no cancerous cells are left at the edges of the removed tissue, is critical to a patient's long-term health outcome but poses a significant surgical challenge. 'We believe our innovative real-time microscopic imaging platform represents a genuine breakthrough in surgical cancer management by bringing live cellular imaging to the bedside.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah Using topical dyes, the removed tissue will then be examined with the InForm device to back up the InVue imaging. The additional InForm pathology data will be fed back into the company's imaging and pathology workflows ahead of its FDA application. The study will also incorporate InForm imaging of tissue samples taken chairside or from pathology laboratories to match its other ex vivo patient data. InForm can assess new tissue samples quickly and accurately with high resolution and magnification. While each device was designed to operate independently, Optiscan says it purposefully included both in the trial to maximise data collection, minimise the need to recruit patients into further trials and accelerate its regulatory submissions.
The Age
3 days ago
- The Age
Melbourne breast cancer trial to test Optiscan imaging device
ASX-listed medical technology company Optiscan Imaging has started recruiting up to 50 patients for a Royal Melbourne Hospital clinical trial of its innovative precision surgery and digital pathology imaging devices, aiming to improve a common breast cancer surgery. The groundbreaking clinical study will utilise Optiscan's InVue microscopic precision surgery device, as well as its InForm digital pathology imaging system, to create a new, improved treatment regimen for breast cancer patients. The company will investigate the clinical workflow and real-time imaging capabilities of the two platforms in its first in-human breast cancer study. Optiscan will use data from the trial in its submissions for United States Food and Drug Administration (FDA) registration for the devices. Surgeons will use the InVue device during surgery to capture live imaging data from a woman's breast tissue after removing a tumour. It will provide the surgical team with immediate feedback on tumour clearance, ensuring there is a margin of healthy breast tissue around the site where the tumour was removed. Achieving a clear surgical margin, where no cancerous cells are left at the edges of the removed tissue, is critical to a patient's long-term health outcome but poses a significant surgical challenge. 'We believe our innovative real-time microscopic imaging platform represents a genuine breakthrough in surgical cancer management by bringing live cellular imaging to the bedside.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah Using topical dyes, the removed tissue will then be examined with the InForm device to back up the InVue imaging. The additional InForm pathology data will be fed back into the company's imaging and pathology workflows ahead of its FDA application. The study will also incorporate InForm imaging of tissue samples taken chairside or from pathology laboratories to match its other ex vivo patient data. InForm can assess new tissue samples quickly and accurately with high resolution and magnification. While each device was designed to operate independently, Optiscan says it purposefully included both in the trial to maximise data collection, minimise the need to recruit patients into further trials and accelerate its regulatory submissions.
The Age
23-06-2025
- The Age
Optiscan teams up with US drugmaker to support FDA submissions
Optiscan Imaging has fired a major shot in a bid to expand into the lucrative United States medical imaging market by inking a blockbuster five-year deal with American pharmaceutical outfit Long Grove Pharmaceuticals. The exclusive collaborative agreement will see Long Grove's fluorescein sodium contrast dye, AK-FLUOR, supplied for use in Optiscan's InVue imaging system in clinical studies, starting with breast surgery. Long Grove was founded by US healthcare investor Water Street and is known for its high-quality, cost-effective drug formulations. The company is the legal manufacturer of AK-FLUOR dye. The contrast dye is used to highlight cellular structures for medical imaging during surgery. Optiscan already uses the dye with its InVue fluorescence-based endomicroscopic imaging technology. 'AK-FLUOR will be used in combination with our fluorescence-based endomicroscopic imaging devices to undertake studies and clinical trials.' Optiscan chief executive officer and managing director Dr Camile Farah The two companies have teamed up to explore and support new clinical uses for the injectable dye and will initially focus on breast surgery. The deal is expected to expand into gastrointestinal endoscopy, robotic-assisted surgery and laparoscopic procedures. The data generated from the trials will be used to fast-track United States Food and Drug Administration (FDA) approvals for both the device and the drug, potentially unlocking broader commercial use and a quicker route into the US market. As part of the deal, Optiscan will get valuable information about how AK-FLUOR works in the body and how it's manufactured. In return, Long Grove will receive support for new FDA applications if new therapeutic uses of its drug in microscopic imaging come to light from the trials. Optiscan chief executive officer and managing director Dr Camile Farah said: 'For Optiscan, the agreement gives us a supply of Long Grove's AK-FLUOR, which will be used in combination with our fluorescence-based endomicroscopic imaging devices to undertake studies and clinical trials. The data flowing from these studies will be an invaluable resource for our regulatory submissions. For Long Grove, the collaboration should hopefully identify new uses for its drug.'
